NTAC Releases Adoption Pack to Assist Implementation of NICE Guidelines Supporting the Use of EXOGEN
HOOFDDORP, THE NETHERLANDS – (May 13, 2013) – The NHS Technology Adoption Centre (NTAC), the implementation arm of the National Institute for Health and Care Excellence (NICE), recently launched a new Adoption Pack regarding the EXOGEN Ultrasound Bone Healing System.
The new adoption pack is designed to help NHS Trusts correctly implement guidelines NICE released (guidance MTG12) supporting the use of EXOGEN as an alternative to surgery for thousands of patients with long bone non-union fractures. The pack includes information about the benefits of EXOGEN to patients/physicians/healthcare systems, the national and local opportunities available, the drivers for adoption, detailed case studies of where EXOGEN has already been successfully used in the NHS, and the costs and potential savings.
NTAC’s experience of working with NHS clinicians, managers and commissioners ensures the information and advice contained within the Adoption Pack is accurate and useful for the NHS.
EXOGEN, which is manufactured and distributed worldwide by Bioventus LLC, uses a unique low-intensity pulsed ultrasound signal to stimulate broken bones to heal naturally, in comparison to surgical management. Patients using EXOGEN place an ultrasound probe on the skin for 20 minutes a day and the treatment, done at home, is entirely pain free with no known side effects. Clinical studies have shown EXOGEN to have an equivalent 86% success rate as surgery1.
The device is used by physicians around the world including many of the UK’s leading surgeons, a number of which have been interviewed for the Adoption Pack. One of these is Angus MacLean, Senior Orthopaedic Consultant at Glasgow Royal Infirmary, who said: “By accelerating health there is significant potential for this technology to save money for the NHS by reducing the need for surgery and returning patients to work more quickly than before. Cost savings and clinical effectiveness therefore make a potential ‘win-win’ situation for the NHS and the patient.”
Bioventus is a biologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company’s innovative products include market-leading devices, therapies and diagnostics that make it a global leader of active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behaviour, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com.
1. Nolte PA, van der Krans A, Patka P, Janssen JMC, Ryaby JP, Albers GHR. Low-intensity ultrasound in the treatment of nonunions. J Trauma 2001;51:693–703.
EXOGEN is a registered trademark of Bioventus LLC
EXOGEN summary of indications for use in the EU:
EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of osseous defects (excluding vertebra and skull) that includes: Treatment of delayed union and non-unions, accelerating the time to heal of fresh fractures, treatment of stress fractures, accelerating repair following osteotomy, accelerating repair in bone transport procedures, accelerating repair in distraction osteogenesis procedures, treatment of joint fusion. There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found at www.healmybone.com.